Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights.

ABSTRACT:

Background

We investigated the association between serum MUC5AC (sMUC5AC) levels and patient outcomes in individuals who underwent resection for pancreatic ductal adenocarcinoma (PDA), including those treated with neoadjuvant therapy (NAT) and those who had upfront surgery (UpS) followed by adjuvant therapy.

Methods

Serum samples from the Ohio State University biorepository collected from January 2010 to June 2021 were utilized. The human MUC5AC kit (NBP2-76703) was used to perform enzyme-linked immunoassays to measure sMUC5AC levels. Logistic regression, Cox regression models (univariate and multivariate), recurrence prediction, analysis of variance (ANOVA), t-tests, and Wilcoxon tests were used for statistical analysis.

Results

In the NAT cohort (n = 23), elevated s

SUBMITTER: Manne A 

PROVIDER: S-EPMC12010103 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature